Figure 1From: An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A Diagram of the study design. The number of CMT1A patients randomised to each group and reasons for withdrawal are indicated.Back to article page